12.10

11.11% 1.21

Oric Pharmaceuticals Inc (ORIC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.89

Offen:

$10.94

24-Stunden-Volumen:

3.61M

Relative Volume:

2.23

Marktkapitalisierung:

$1.25B

Einnahmen:

Nettoeinkommen (Verlust:

$-135.21M

KGV:

-8.455

EPS:

-1.4311

Netto-Cashflow:

$-114.35M

1W Leistung:

+12.77%

1M Leistung:

+28.31%

6M Leistung:

+0.92%

1J Leistung:

+3.15%

1-Tages-Spanne:

$10.74

$12.55

1-Wochen-Bereich:

$10.37

$12.55

52-Wochen-Spanne:

$7.23

$14.93

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Firmenname

Oric Pharmaceuticals Inc

Sektor

Healthcare (1071)

Branche

Biotechnology (598)

Telefon

(650) 388-5600

Adresse

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Mitarbeiter

104

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

ORIC's Discussions on Twitter

Compare ORIC vs VRTX, REGN, ARGX, RVMD, ALNY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ORIC Oric Pharmaceuticals Inc	12.10	1.25B	0	-135.21M	-114.35M	-1.4311
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-06-12	Fortgesetzt	Stifel	Buy
2026-05-15	Hochstufung	Goldman	Neutral → Buy
2026-01-07	Eingeleitet	Piper Sandler	Overweight
2025-11-20	Eingeleitet	Evercore ISI	Outperform
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-09-04	Fortgesetzt	Guggenheim	Buy
2025-07-08	Eingeleitet	Ladenburg Thalmann	Buy
2024-10-31	Eingeleitet	Wells Fargo	Overweight
2024-09-06	Eingeleitet	Stifel	Buy
2024-02-23	Eingeleitet	Cantor Fitzgerald	Overweight
2023-09-22	Eingeleitet	Wedbush	Outperform
2023-03-23	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-03-21	Hochstufung	Guggenheim	Neutral → Buy
2023-03-16	Hochstufung	Oppenheimer	Perform → Outperform
2022-07-18	Fortgesetzt	Oppenheimer	Perform
2022-04-04	Hochstufung	Citigroup	Neutral → Buy
2022-03-25	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-03-22	Herabstufung	Citigroup	Buy → Neutral
2022-03-22	Herabstufung	Guggenheim	Buy → Neutral
2022-03-22	Herabstufung	Oppenheimer	Outperform → Perform
2021-07-06	Hochstufung	Citigroup	Neutral → Buy
2021-01-25	Herabstufung	Citigroup	Buy → Neutral
2020-08-13	Eingeleitet	Robert W. Baird	Outperform
2020-08-06	Hochstufung	Citigroup	Neutral → Buy
2020-08-03	Eingeleitet	H.C. Wainwright	Buy
2020-05-19	Eingeleitet	Citigroup	Neutral
2020-05-19	Eingeleitet	Guggenheim	Buy
2020-05-19	Eingeleitet	JP Morgan	Overweight
2020-05-19	Eingeleitet	Jefferies	Buy

Alle ansehen

Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten

02:08 AM

Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat

Jul 24, 2026

Jul 22, 2026

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits

Jul 22, 2026

Jul 21, 2026

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha

Jul 21, 2026

Jul 20, 2026

Oric Pharmaceuticals stock trades down to 10.69 as oricpharma promotes BTIG conference meeting - Traders Union

Jul 20, 2026

Discipline and Rules-Based Execution in ORIC Response - Stock Traders Daily

Jul 20, 2026

ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire

Jul 20, 2026

Oric Pharmaceuticals (ORIC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Jul 20, 2026

Jul 16, 2026

How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - Sahm

Jul 16, 2026

ORIC Launches Phase 3 Himalayas-1 Trial - t.co

Jul 16, 2026

Jul 15, 2026

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer - Sahm

Jul 15, 2026

Oric Pharmaceuticals (ORIC) Launches Phase 3 Trial for Prostate Cancer Treatment - GuruFocus

Jul 15, 2026

Jul 14, 2026

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial - Investing.com

Jul 14, 2026

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial By Investing.com - Investing.com India

Jul 14, 2026

Bayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial - Stock Titan

Jul 14, 2026

Jul 08, 2026

Oric Pharmaceuticals director Heyman sells $3,600 in stock - Investing.com

Jul 08, 2026

Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa

Jul 08, 2026

Oric Pharmaceuticals director Heyman sells $3,600 in stock By Investing.com - Investing.com India

Jul 08, 2026

Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan - Stock Titan

Jul 08, 2026

Jul 07, 2026

Price to sales forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jul 07, 2026

ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - Ad Hoc News

Jul 07, 2026

Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView

Jul 07, 2026

Jul 06, 2026

Form 144 Oric Pharmaceuticals For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan

Jul 06, 2026

[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan

Jul 06, 2026

ORIC Pharmaceuticals Slips 2.49% as Stock Tests Key Support LevelsBreakout Stock Alerts - DonanımHaber

Jul 06, 2026

Jul 03, 2026

Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union

Jul 03, 2026

Jul 02, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 02, 2026

ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan

Jul 02, 2026

ORIC Pharmaceuticals grants stock options and r... - Pluang

Jul 02, 2026

Jun 29, 2026

Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN

Jun 29, 2026

Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jun 29, 2026

Jun 28, 2026

Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026

Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026

Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026

Behavioral Patterns of ORIC and Institutional Flows - Stock Traders Daily

Jun 28, 2026

Jun 26, 2026

ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN

Jun 26, 2026

Oric Pharmaceuticals stock trades up as price holds above key supports despite mixed momentum - Traders Union

Jun 26, 2026

Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC) - TradingView

Jun 26, 2026

Jun 25, 2026

ORIC Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Jun 24, 2026

Jun 22, 2026

Oric Shareholders Approve Equity Plan, Governance Measures - TipRanks

Jun 22, 2026

ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay - Stock Titan

Jun 22, 2026

Jun 21, 2026